Document Detail


Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
MedLine Citation:
PMID:  8860738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Staging in patients with newly diagnosed untreated cancer of the prostate has significant ramifications on the management of the disease. Currently measurement of the serum prostate-specific antigen (PSA) concentration and radionuclide bone scan are two important procedures in the metastatic workup of these patients. We retrospectively evaluated the efficacy of PSA as a staging marker to discriminate prostate cancer patients with bone metastases from those without bone metastases. MATERIALS AND METHODS: In a retrospective study 158 prostate cancer patients with (n = 21) and without (n = 137) bone metastases were analyzed. In all patients the initial PSA measurement as well as the radionuclide bone scan were evaluated. RESULTS: Patients with bone metastases demonstrated a median serum PSA concentration of 151 ng/ml and only 1 patient revealed a serum PSA concentration of <10 ng/ml. This resulted in a negative predictive value of 98%. In addition 67% of these patients demonstrated a serum PSA concentration of >100 ng/ml, which resulted in a positive predictive value of 74% and an overall accuracy of 92%. CONCLUSION: The serum PSA concentration seems to provide useful information with regard to the presence of bone metastasis in patients with newly diagnosed cancer of the prostate. A serum PSA value of <10 ng/ml nearly excludes bone metastases, whereas a serum PSA value of> 100 ng/ml is highly predictive of bone metastases.
Authors:
J M Wolff; R Bares; P K Jung; U Buell; G Jakse
Related Documents :
20683058 - Preliminary results of tranilast treatment for patients with advanced castration-resist...
9436288 - Radical prostatectomy as treatment for prostate-specific antigen-detected stage t1c pro...
15780158 - Screening for prostate cancer: updated experience from the tyrol study.
15220358 - Technical variations in prostatic immunohistochemistry: need for standardisation and st...
17625788 - Novel hyaluronic acid (ha) coated drug carriers (hcdcs) for human breast cancer treatment.
21863088 - 1,3‑propane sultone.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Urologia internationalis     Volume:  56     ISSN:  0042-1138     ISO Abbreviation:  Urol. Int.     Publication Date:  1996  
Date Detail:
Created Date:  1997-02-19     Completed Date:  1997-02-19     Revised Date:  2006-10-30    
Medline Journal Info:
Nlm Unique ID:  0417373     Medline TA:  Urol Int     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  169-73     Citation Subset:  IM    
Affiliation:
Departments of Urology, Aachen University of Technology, Aachen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Bone Neoplasms / diagnosis*,  radionuclide imaging,  secondary*
Humans
Male
Middle Aged
Predictive Value of Tests
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / immunology,  pathology*
ROC Curve
Retrospective Studies
Sensitivity and Specificity
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of ureteropelvic transitional cell carcinoma with bladder transitional cell carcinoma usi...
Next Document:  Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-bas...